financetom
Business
financetom
/
Business
/
Encore Capital Group, Inc. Announces Pricing of Upsized Senior Secured Notes Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Encore Capital Group, Inc. Announces Pricing of Upsized Senior Secured Notes Offering
Sep 24, 2025 4:04 PM

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Encore Capital Group, Inc. ( ECPG ) (the “Company”) today announced the pricing of its offering of $500.0 million aggregate principal amount of 6.625% senior secured notes due 2031 (the “notes”), which was upsized by $100.0 million from $400.0 million, at an issue price of 100.00% in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and outside the United States to non-U.S. persons (within the meaning of Regulation S under the Securities Act).

The notes will be senior secured obligations of the Company, and will be fully and unconditionally guaranteed on a senior secured basis by substantially all material subsidiaries of the Company. The obligations of the Company and the guarantors will be secured, together with the Company’s other senior secured indebtedness, by substantially all of the assets of the Company and the guarantors. The notes will accrue interest at a rate of 6.625% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2026. The notes will mature on April 15, 2031 unless earlier repurchased or redeemed by the Company.

The Company intends to use the proceeds from this offering to repay drawings under its revolving credit facility (the "Global Senior Facility") and to pay certain transaction fees and expenses incurred in connection with the offering of the notes.

The offer and sale of the notes have not been, and will not be, registered under the Securities Act, and the notes may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes nor will there be any sale of the notes in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. Any offer of the securities will be made only by means of a private offering memorandum.

Forward-Looking Statements

This press release includes forward-looking statements, including statements regarding the completion, timing and size of the proposed offering, the intended use of the proceeds and the terms of the notes being offered. Forward-looking statements represent Encore’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, including market interest rates, the trading price and volatility of Encore’s common stock and risks relating to Encore’s business, including those described in periodic reports that Encore files from time to time with the U.S. Securities and Exchange Commission. Encore may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding the final terms of the notes or its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Encore does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.

Contact Information

Bruce Thomas, Investor Relations

(858) 309-6442

[email protected]

Image: https://www.globenewswire.com/newsroom/ti?nf=OTUzNDkwMSM3MTY0MDY5IzIwMDQ3NDU=

Image: https://ml.globenewswire.com/media/NDA3ZWU0YWEtMzkwNi00MmQxLTk5Y2MtY2FlZWU5ZDJmZWRlLTEwMTYzMTgtMjAyNS0wOS0yNC1lbg==/tiny/Encore-Capital-Group-Inc-.png Image: Primary Logo

Source: Encore Capital Group, Inc. ( ECPG )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Saia CFO Douglas Col to Retire
Saia CFO Douglas Col to Retire
Apr 26, 2024
09:17 AM EDT, 04/26/2024 (MT Newswires) -- Saia ( SAIA ) said Friday that its chief financial officer, Douglas Col, will retire after 10 years with the transportation company. The company said Col will remain as CFO until a successor is named and will also serve as an advisor until the end of the year to ensure a smooth transition....
Estee Lauder, Microsoft Expand Collaboration to Create AI Innovation Lab
Estee Lauder, Microsoft Expand Collaboration to Create AI Innovation Lab
Apr 26, 2024
09:26 AM EDT, 04/26/2024 (MT Newswires) -- Estee Lauder ( EL ) and Microsoft ( MSFT ) are expanding their global strategic collaboration with the creation of an artificial intelligence innovation lab, the companies said Friday. Under the terms of the partnership, the companies will provide services by leveraging Microsoft's ( MSFT ) Azure OpenAI for Estee Lauder's ( EL...
BRIEF-Nova Leap Health Announces Execution Of Definitive Agreement
BRIEF-Nova Leap Health Announces Execution Of Definitive Agreement
Apr 26, 2024
April 26 (Reuters) - Nova Leap Health Corp ( NVLPF ): * NOVA LEAP HEALTH CORP. ( NVLPF ) ANNOUNCES EXECUTION OF DEFINITIVE AGREEMENT * NOVA LEAP HEALTH CORP ( NVLPF ) - TO ACQUIRE A HOME CARE SERVICES COMPANY WITH OPERATIONS IN MASSACHUSETTS Source text for Eikon: Further company coverage: ...
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy
Apr 26, 2024
09:15 AM EDT, 04/26/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Friday that a European regulator has recommended approval of Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients having unresectable or metastatic urothelial carcinoma. The positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use is based on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved